BS01 in Patients With Retinitis Pigmentosa

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2029

Conditions

Retinitis Pigmentosa

Interventions

DRUG

BS01

Non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector expressing an enhanced light-sensitive channelrhodopsin gene (ChronosFP)

Trial Locations (1)

New Jersey Retina, Teaneck